The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
Status:
Enrolling by invitation
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is a single institutional, single arm, open labeled phase II study to assess the overall
radiographic response of adding Avelumab to chemotherapy and palliative radiotherapy in
patients with metastatic advanced esophageal squamous cell carcinoma.